No. A baby cannot survive with bilateral renal agenesis (BRA) without life support, and survival without renal replacement therapy is not achievable because the kidneys never form to filter blood or make urine. This is a bilateral absence of both kidneys, a developmental failure rather than a disease that damages working organs. Current medical practice treats the condition as life-limiting: death without intervention typically comes from pulmonary hypoplasia and respiratory failure within hours to days of birth. The only documented survivors are infants supported from birth by experimental dialysis, then kidney transplant.
What bilateral renal agenesis means developmentally
The kidneys do not appear and then fail. They never form at all, because the structure that induces them fails early. Around the fifth week of human development, a duct called the ureteric bud grows out of the mesonephric duct and contacts a mass of intermediate mesoderm, the metanephric mesenchyme. That contact triggers the mesenchyme to condense and eventually become nephrons, the filtering units. Remove the bud-mesenchyme interaction and no kidney forms.
In bilateral renal agenesis, the ureteric bud fails to emerge or fails to reach the mesenchyme on both sides. The mesenchyme then undergoes programmed cell death. No glomeruli, no tubules, and no collecting system develop. The bladder may be absent or severely underdeveloped, and the ureters are usually missing. The word agenesis is the key: this is absent formation, not reduced formation. A related but distinct condition, renal hypoplasia, involves kidneys that are present but small.
The downstream consequence is mechanical. From roughly the middle of the second trimester, fetal urine is the main source of amniotic fluid. Without kidneys, the fetus makes almost no urine. The result is severe oligohydramnios, sometimes called anhydramnios when fluid is essentially absent. Amniotic fluid is not just padding. It inflates the lungs as they develop, keeps the umbilical cord free, and allows the fetus to move. Lose it early enough and lung growth is arrested.
Typical detection happens on a second-trimester anatomy scan around 18 to 22 weeks. Ultrasound shows an empty renal fossa where the kidneys should be, a small or absent bladder, and low fluid. Color Doppler finding absent renal arteries supports the diagnosis. Amniotic fluid volume is usually graded by deepest vertical pocket and amniotic fluid index; for reference, a deepest vertical pocket of 2 cm or less, or an amniotic fluid index of 5 cm or less, defines oligohydramnios. In true BRA the values often sit near zero.
The lung problem is the reason this condition is lethal, and it deserves a precise explanation. Fetal lungs develop partly by branching of the airways and partly by stretch. Fluid secreted inside the lung, plus the pressure of surrounding amniotic fluid, provides that stretch. When amniotic fluid is chronically absent, the chest wall compresses the lungs, airway branching is reduced, and the number of alveoli and the size of the pulmonary vascular bed fall. The infant is born with hypoplastic lungs: small, stiff, and poorly vascularized. This is why a baby with BRA often dies of respiratory failure before the missing kidneys cause symptoms.
The quantified clinical context
Outcome numbers for bilateral renal agenesis are stark but should be read with care, because published series differ in how cases were ascertained. The classic teaching is that untreated BRA is uniformly fatal, with death from respiratory failure within minutes to hours of birth. Many infants survive a few days on mechanical ventilation, and a minority reach weeks with aggressive support. The larger and older case series generally report death in the first days of life, and this pattern has been stable for decades.
Epidemiology is where precision matters. Bilateral renal agenesis is often grouped with the broader category of renal agenesis, which includes unilateral cases. Unilateral renal agenesis is far more common than bilateral. Population-based birth defect registries and studies of the renal agenesis spectrum report BRA at roughly 1 in 3,000 to 1 in 10,000 births, with substantial regional variation. The condition occurs more often in pregnancies with oligohydramnios and more often in male fetuses in many series.
The genetics are heterogeneous and often sporadic. Many cases have no identified cause. Some occur as part of syndromes, and some are associated with variants in genes such as RET, which is involved in ureteric bud outgrowth. A small but real fraction is linked to maternal diabetes, which raises the risk of renal anomalies generally. For families planning future pregnancies, the recurrence risk depends on the cause and ranges from low in isolated sporadic cases to 25 percent in autosomal recessive syndromes. These are general ranges, not predictions for any individual.
One counterintuitive detail: the absence of kidneys is often not the immediate cause of death on a birth certificate. Infants with BRA typically die of respiratory failure and pulmonary hypoplasia, and the renal failure is secondary in timing. This is why the modern experimental strategy targets the lungs first and the kidneys second.
Edge cases: where the arithmetic of survival changes
Survival is not zero, but it is rare and dependent on extraordinary support. A handful of case reports describe infants with BRA who survived the newborn period on peritoneal dialysis started within days of birth, followed later by kidney transplant. These are highly selected patients, often with milder lung involvement than typical, and the published literature does not allow a reliable survival rate. The honest statement is that survival without dialysis is not documented, and survival with dialysis plus transplant has been reported but is exceptional.
The main driver of that variability is the timing and severity of oligohydramnios. A fetus who loses amniotic fluid late in the third trimester may have lungs that developed enough to support life for a time. A fetus with anhydramnios from 16 weeks has almost no chance of adequate lung growth. This is a continuum, not a binary, and it is why second-trimester ultrasound timing matters so much for counseling.
Related diagnoses matter for framing. Bilateral renal agenesis is distinct from multicystic dysplastic kidneys, in which kidney tissue is present but malformed, and from polycystic kidney disease, in which kidneys are enlarged. Autosomal recessive polycystic kidney disease can also cause severe oligohydramnios, but the kidneys exist. The distinction affects counseling, because the underlying mechanism and recurrence risk differ.
A professional caveat worth stating plainly: some published reviews of the renal agenesis spectrum undercount bilateral cases because registry reporting varies and because many pregnancies with severe anomalies are terminated before birth. That makes prevalence estimates uncertain and makes the fatal-outcome statistics apply most directly to infants who reach delivery alive.
Red flags to watch for in prenatal imaging:
Empty renal fossae at the 18 to 22 week anatomy scan with severe oligohydramnios. Absent or nonvisualized fetal bladder across sequential ultrasounds. An amniotic fluid index near or below 5 cm or a deepest vertical pocket of 2 cm or less. Absent renal arteries on Doppler, or a compressed fetal chest with a bell-shaped thorax. A history of a prior child with renal agenesis or a known familial renal anomaly gene variant.
Comparing outcomes for similar renal presentations
| Presentation | Kidney tissue at birth | Typical amniotic fluid | Newborn course without transplant | Documented transplant survivors |
|---|---|---|---|---|
| Bilateral renal agenesis | None | Severe oligohydramnios or none | Respiratory failure; death typically hours to days | Rare, case reports |
| Bilateral multicystic dysplastic kidneys | Present but nonfunctional | Often low | Dialysis-dependent from birth | Reported in selected cases |
| Bilateral renal hypoplasia | Reduced | Variable | Depends on residual function | Possible with progression to failure |
| Unilateral renal agenesis | One normal kidney | Usually normal | Generally normal life | Not applicable |
| Autosomal recessive polycystic kidney disease | Enlarged, cystic | Low in severe forms | Respiratory compromise common | Select cases over time |
The table is a framework, not a set of guarantees. Mild and severe forms exist within each row.
Timeline of clinical events from diagnosis to delivery
| Stage | Typical timing | What happens |
|---|---|---|
| Organ induction failure | Around weeks 5 to 6 of gestation | Ureteric bud fails to reach metanephric mesenchyme; no kidney forms |
| First suggestive ultrasound | Weeks 12 to 16 | Low fluid and nonvisualized bladder may prompt referral |
| Diagnostic anatomy scan | Weeks 18 to 22 | Empty renal fossae, absent bladder, severe oligohydramnios |
| Second-trimester counseling | Weeks 19 to 24 | Maternal-fetal medicine consultation and genetic evaluation |
| Continued gestation | Third trimester | Lung hypoplasia progresses as fluid stays low |
| Delivery | Term or earlier | Infant often needs immediate respiratory support |
| Newborn period | First hours to days | Death from respiratory failure is the common outcome without extraordinary measures |
Misconceptions worth correcting
The most common misconception is that dialysis or a transplant can reliably rescue these infants, so the condition is survivable with modern medicine. The evidence base for that claim is thin. A few reported survivors exist, but the published record does not establish outcomes or rates, and the interventions involved are highly specialized and not universally available. Presenting BRA as routinely treatable overstates what the literature supports.
Another misconception is that the kidneys alone are the problem. The lethal lesion is pulmonary hypoplasia, driven by low amniotic fluid. Infants die of small, stiff lungs and pulmonary hypertension, not of the direct toxins of renal failure on day one. This is why interventions that increase amniotic fluid, such as serial amnioinfusion, are studied as a way to buy lung development and are not proven.
A third issue is conflating unilateral and bilateral disease. Unilateral renal agenesis is usually compatible with a normal life because the remaining kidney undergoes compensatory growth. Bilateral disease is a different entity with a different prognosis, and mixing the two in counseling or in reading search results leads to false reassurance.
A fourth is the assumption that a normal 20-week scan proves normal kidneys. In severe oligohydramnios, ultrasound windows are poor and the bladder may be empty for reasons other than agenesis. Follow-up imaging, and occasionally fetal MRI, are used to clarify anatomy. Diagnostic certainty is a process, not a single image.
Practical actions for expectant and delivering families
The first practical step is referral to maternal-fetal medicine and, ideally, a pediatric nephrology and neonatology team before delivery. Prenatal diagnosis of BRA should trigger genetic counseling, because identifying a syndrome changes recurrence counseling and informs delivery planning. Amniocentesis for chromosomal microarray and, where indicated, targeted gene testing is typically offered.
The second step is delivery planning. A center with level III or IV neonatal intensive care and pediatric nephrology capability allows honest discussion of whether respiratory support, dialysis, and eventual transplant candidacy are realistic. Some families choose comfort-focused newborn care; others pursue aggressive support. Both are legitimate decisions, and the conversation should include the documented rarity of survival.
Concrete thresholds help frame that conversation. Severe oligohydramnios before 24 weeks carries the worst prognosis for lung development. Delivery before 32 weeks adds prematurity-related lung disease on top of hypoplasia. An infant with a birth weight under 1,500 grams faces additional respiratory and dialysis complications. These are prognostic factors, not rules.
The third step is preparing for the first minutes after birth. Respiratory support (continuous positive airway pressure or mechanical ventilation), vascular access, and, in rare cases, early dialysis are typically discussed. Peritoneal dialysis requires a functional peritoneal cavity and is often feasible only after postnatal stabilization. Kidney transplant is never an option in the newborn period; it is considered only after the child stabilizes and grows, and only in centers with pediatric transplant programs.
The fourth step is documentation and coordination. Written delivery-plan notes, a clear record of the prenatal diagnosis, and early involvement of palliative care, if chosen, reduce confusion in the delivery room.
Limitations of what can be concluded
The evidence base for bilateral renal agenesis is limited by its rarity, by variable registry reporting, and by the ethics of studying a lethal condition. Most published outcome data come from case series rather than controlled trials. The handful of reported survivors after dialysis and transplant are important but cannot be used to estimate a general survival rate.
Several specific uncertainties should be stated plainly. The exact proportion of infants who survive the first year with maximal support is not known from high-quality data. The long-term outcomes of the few transplant survivors are learning-based, not proven. The effectiveness of serial amnioinfusion to prevent pulmonary hypoplasia remains unproven and is under study. Genetic causes are identifiable in only a fraction of cases, so recurrence counseling can be precise for some families and uncertain for others.
What can be concluded is more durable. Without kidneys, urine production fails, amniotic fluid falls, and lung development is compromised. That sequence explains the mortality pattern far better than the renal failure alone. The condition is a developmental failure, not a treatable acquired disease, and current practice reflects that reality while research continues to test whether any intervention can change it.
Where does that leave the answer to the search question? Bilateral renal agenesis is not survivable without extraordinary, rare, and experimental support, and even with it, survival is exceptional rather than expected. Families and clinicians should plan around that reality while recognizing that the smallest number of reported survivors exists and that future research may shift the boundary, not erase it.